^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mesna

    Company:
    Generic mfg.
    Drug class:
    Antioxidant
    Related drugs:
    5d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    13d
    PRESERVE I: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    13d
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    17d
    Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov)
    P2, N=41, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • melphalan • mesna • Neupogen (filgrastim)
    17d
    Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim) • methylprednisolone sodium succinate
    28d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Dec 2025 --> May 2026
    Trial initiation date
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    1m
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Washington University School of Medicine | Phase classification: P1/2 --> P1 | N=35 --> 6 | Trial completion date: Jan 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Mar 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    1m
    OPTIMIZE: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (clinicaltrials.gov)
    P2, N=313, Active, not recruiting, Center for International Blood and Marrow Transplant Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    1m
    Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    gemcitabine • Rituxan (rituximab) • ifosfamide • oxaliplatin • etoposide IV • mesna • Duoenda (mitoxantrone liposomal)
    1m
    Primary Renal Synovial Sarcoma: A Report of a Rare Case and Management Approach. (PubMed, Cureus)
    Postoperatively, the patient received adjuvant chemotherapy with the AIM (doxorubicin, ifosfamide, and mesna) regimen. Given the extreme rarity of PRSS, we discuss the diagnostic challenges, molecular characteristics, and treatment approach adopted at our institution, contributing to the limited but growing body of knowledge on this rare entity.
    Journal
    |
    SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    doxorubicin hydrochloride • ifosfamide • mesna
    2ms
    An evidence-based approach to pericardial synovial sarcoma: a unique case report. (PubMed, Ecancermedicalscience)
    The chemotherapy regimen of ifosfamide, mesna and doxorubicin proved effective for this condition, leading to a significant reduction in tumour size and metabolic activity. However, due to disease recurrence and the presence of a KDM5A-positive marker, second-line therapy with trabectedin and pazopanib became necessary.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • KDM5A (Lysine Demethylase 5A) • CD99 (CD99 Molecule) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    doxorubicin hydrochloride • pazopanib • ifosfamide • Yondelis (trabectedin) • mesna
    2ms
    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna • busulfan